Review of EMERALD Subgroup Analysis Data From SABCS 2023

Opinion
Video

Subgroup analyses from the EMERALD trial show that oral SERD elacestrant may outperform standard endocrine therapy in metastatic breast cancer patients with bone or visceral metastases who previously received CDK4/6 inhibitors.

Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content